Keynote 564 Trial News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Keynote 564 trial. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Keynote 564 Trial Today - Breaking & Trending Today

Adjuvant Pembrolizumab Improves OS in Select Patients With RCC After Nephrectomy

Adjuvant treatment with pembrolizumab significantly improved overall survival vs placebo in patients with renal cell carcinoma at intermediate-high or high risk of recurrence after nephrectomy, or after nephrectomy and resection of metastatic lesions, meeting a key secondary end point of the phase 3 KEYNOTE-564 trial. ....

Merck Research Laboratories , Cancers Symposium , Adjuvant Pembrolizumab , Renal Cell Carcinoma , Genitourinary Cancer , Keynote 564 Trial , Asco Gu , 2023 Genitourinary Cancers Symposium , Fda Approval ,

Post-Hoc Analysis Supports Adjuvant Pembrolizumab in ccRCC at Increased Risk of Recurrence

Adjuvant pembrolizumab prolonged disease-free survival and distant metastasis–free survival vs placebo in patients with clear cell renal cell carcinoma at increased risk of recurrence after nephrectomy, irrespective of UCLA Integrated Staging System risk category and disease stage. ....

United States , Dana Farber Cancer Institute , Nancy Kohlberg , Toni Choueiri , Kidney Cancer Center , Professor Of Medicine At Harvard Medical School , Lank Center , American Joint Committee On Cancer , Staging System , Cancers Symposium , American Joint Committee , Genitourinary Oncology , Nancy Kohlberg Chair , Harvard Medical School , Clear Cell Renal Carcinoma , Renal Cell Carcinoma , Ucla Integrated Staging System , Keynote 564 Trial , Asco Gu ,